Aktis Oncology, Inc. Common stock (AKTS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aktis Oncology, Inc. Common stock stock (AKTS) is currently trading at $18.63. Aktis Oncology, Inc. Common stock PS ratio (Price-to-Sales) is 175.63. Analyst consensus price target for AKTS is $31.25. WallStSmart rates AKTS as Sell.
- AKTS PE ratio analysis and historical PE chart
- AKTS PS ratio (Price-to-Sales) history and trend
- AKTS intrinsic value — DCF, Graham Number, EPV models
- AKTS stock price prediction 2025 2026 2027 2028 2029 2030
- AKTS fair value vs current price
- AKTS insider transactions and insider buying
- Is AKTS undervalued or overvalued?
- Aktis Oncology, Inc. Common stock financial analysis — revenue, earnings, cash flow
- AKTS Piotroski F-Score and Altman Z-Score
- AKTS analyst price target and Smart Rating
Aktis Oncology, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Aktis Oncology, Inc. Common stock (AKTS) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Aktis Oncology, Inc. Common stock (AKTS) Key Strengths (0)
Supporting Valuation Data
Aktis Oncology, Inc. Common stock (AKTS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 175.6x annual revenue
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 43.20%
Supporting Valuation Data
Aktis Oncology, Inc. Common stock (AKTS) Detailed Analysis Report
Overall Assessment
This company scores 11/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 0 register as strengths (avg 0/10) while 5 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (175.63) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -26.50%, Operating Margin at -1676.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -26.50% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AKTS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AKTS's Price-to-Sales ratio of 175.63x trades 48% below its historical average of 340.69x (0th percentile). The current valuation is 76% below its historical high of 725.8x set in Jan 2026, and 0% above its historical low of 175.63x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~725.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aktis Oncology, Inc. Common stock (AKTS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aktis Oncology, Inc. Common stock operates as a stable business with moderate growth and solid fundamentals. Revenue reached 6M with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 227% of revenue (13M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -15M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aktis Oncology, Inc. Common stock.
Bottom Line
Aktis Oncology, Inc. Common stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aktis Oncology, Inc. Common stock(AKTS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device industry in the United States. The company is headquartered in Huntersville, North Carolina.